Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support

NCT00003107 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT00003107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support
Lead sponsor
Indiana University
Phase
Phase 1
Overall status
Completed
Start date
October 31, 1997
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chronic myeloproliferative disorders, gestational trophoblastic tumor, kidney cancer, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, neuroblastoma, ovarian cancer, testicular germ cell tumor